Case Reports in Nephrology / 2020 / Article / Tab 1

Case Report

Focal Segmental Glomerulosclerosis in Waldenström’s Macroglobulinemia

Table 1

Clinical studies, types of renal disease, and treatment in Waldenström’s macroglobulinemia.

StudyNumber of patientsPathology seenTreatment

Morel-Maroger et al. [2]16 patients3 amyloidosis
6 nonamyloid glomerular disease (3 cryoglobulinemia)
7 had no detectable lesions
Not available

Higgins et al. [1]44 patients17 amyloidosis
9 nonamyloid glomerular disease
7 tubulointerstitial nephritis
9 non-monoclonal gammopathy-related glomerular disease (1FSGS)
Amyloid glomerulopathy:
Rituximab R
Ituximab
Chemotherapy
Bortezomib
Nonamyloid glomerulopathy:
Steroid
Rituximab
Rituxima
Bendamustine
Bortezomib
Chemotherapy

Vos et al. [3]44 patientsAmyloidosis 11
Cryoglobulinemia 10
Light-chain deposition disease 4
Cast nephropathy 4
TMA 3
Minimal change disease 2
Membranous nephropathy 1
LPL infiltration 8
Light-chain tubulopathy 1
Proteosome inhibitor + rituximab
Alkylator + rituximab
Nucleoside analogue + rituximab
Bendamustine
Single-agent rituximab

LPL: lymphoplasmacytic lymphoma infiltration; TMA: thrombotic microangiopathy.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.